How do I buy Design Therapeutics, Inc. Common Stock (DSGN) stock?

Buying Design Therapeutics, Inc. Common Stock (DSGN) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "DSGN", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy DSGN by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if DSGN is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Design Therapeutics, Inc. Common Stock (DSGN) Stock

Q: What is the minimum investment for DSGN on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Design Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · DSGN

Trade DSGN

Key stats

Market cap: $656.48M
Price / Earnings ratio: -9.5x
EPS (TTM): -$1.19
Volume: Loading
52-week high: $17.25
52-week low: $5.28

Source: third-party data provider, as of October 24, 2026

Compare with DSGN

Technical indicators

RSI 14: 37.63
MACD 12/26/9: -0.73
EMA 9 of MACD: -0.76
MACD histogram: 0.03
SMA 50: $13.20; Price below SMA 50
EMA 50: $12.34; Price below EMA 50
SMA 200: $12.13; Price below SMA 200
EMA 200: $11.72; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 1 analyst rating

Strong Sell0

Sell0

Hold0

Buy1

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2025

0000

Debt & Balance Sheet

Total assets

Total liabilities

2025

271M179M90M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-69.8M

Net income

Earnings

No data available

Source: third-party data provider

About Design Therapeutics, Inc. Common Stock

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

SectorHealthcare

IndustryBiotechnology

Employees55

CEOMr. Pratik Shah Ph.D.

IPO DateMar 26, 2021

HeadquartersCarlsbad, CA

Key Executives

Name	Title	Year Born
Mr. Pratik Shah Ph.D.	Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson	1970
Dr. Sean Jeffries Ph.D.	Chief Operating Officer	1980
Dr. Chris M. Storgard M.D.	Chief Medical Officer	1966
Dr. Aseem Z. Ansari Ph.D.	Co-Founder & Scientific Advisor	—
Ms. Julie D. Burgess CPA	Chief Accounting Officer	—
Mr. Doane Chilcoat Ph.D.	Chief Technology Officer	—
Mr. Mustapha Parekh	General Counsel	—
Dr. Tadimeti S. Rao Ph.D.	Chief Scientific Officer	—
Mr. Jim Kerr	Chief of Manufacturing & Product Development	—
Dr. Chengzhi Zhang Ph.D.	Chief Chemist	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021										+3.8	+5.5	+32.7
2022	-39.5	+6.3	+15.4	-30.3	+0.3	+11.6	+39.2	+9.0	-21.9	-4.5	-7.7	-26.5
2023	-19.7	-11.3	-18.3	+7.3	-20.3	+16.0	+26.0	-67.8	-4.8	-10.5	+18.8	+5.6
2024	-6.7	+15.4	+40.9	-12.4	+11.9	-17.7	+56.9	-5.9	+13.7	+1.7	+15.4	-1.8
2025	-21.4	+3.0	-14.6	+34.6	-20.8	-16.2	+9.9	+44.8	+31.4	-1.3	+43.4	+4.8
2026	+12.2	+0.3	+4.0	+23.5	-21.2	+38.6	-16.9	+18.3	-17.0	-14.3

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Design Therapeutics, Inc. Common Stock (DSGN) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "DSGN", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy DSGN by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Design Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Design Therapeutics, Inc. Common Stock (DSGN) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track DSGN's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Design Therapeutics, Inc. Common Stock (DSGN) Stock

Key stats

Compare with DSGN

Recent news

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Here Are Thursday's Top Wall Street Analyst Research Calls: AON, Apollo Global Managment, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA,

Here Are Thursday's Top Wall Street Analyst Research Calls: AON, Apollo Global Managment, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA,

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Here Are Thursday's Top Wall Street Analyst Research Calls: AON, Apollo Global Managment, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA,

Here Are Thursday's Top Wall Street Analyst Research Calls: AON, Apollo Global Managment, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA,

Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to Squeeze

Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to Squeeze

About Design Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade